PA8816001A1 - Sistemas de administración de drogas que contienen estradiol - Google Patents

Sistemas de administración de drogas que contienen estradiol

Info

Publication number
PA8816001A1
PA8816001A1 PA20098816001A PA8816001A PA8816001A1 PA 8816001 A1 PA8816001 A1 PA 8816001A1 PA 20098816001 A PA20098816001 A PA 20098816001A PA 8816001 A PA8816001 A PA 8816001A PA 8816001 A1 PA8816001 A1 PA 8816001A1
Authority
PA
Panama
Prior art keywords
drug administration
administration systems
containing estradiol
systems containing
obleas
Prior art date
Application number
PA20098816001A
Other languages
English (en)
Inventor
Adrian Funke
Sascha General
Iidiko Terebesi
Christian Zurth
Sofia Alincic-Kunz
Matthias Schaefers
Thomas Holler
Konstanze Diefenbach
Original Assignee
Bayer Schering Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39365963&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8816001(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AG filed Critical Bayer Schering Pharma AG
Publication of PA8816001A1 publication Critical patent/PA8816001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Steroid Compounds (AREA)

Abstract

SISTEMAS DE ADMINISTRACIÓN DE DROGAS EN LA FORMA DE PELÍCULAS DELGADAS SOLUBLES EN AGUA (OBLEAS), QUE CONTIENEN ESTRADIOL, O DERIVADOS DEL MISMO, EN CANTIDADES BAJAS. LAS OBLEAS DE LA PRESENTE INVENCIÓN SON ADECUADAS PARA TRATAR, ALIVIAR O PREVENIR UNA CONDICIÓN FÍSICA EN UN MAMÍFERO HEMBRA CAUSADA POR NIVELES ENDÓGENOS DE ESTRÓGENO INSUFICIENTES.
PA20098816001A 2008-02-13 2009-02-13 Sistemas de administración de drogas que contienen estradiol PA8816001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08002633 2008-02-13

Publications (1)

Publication Number Publication Date
PA8816001A1 true PA8816001A1 (es) 2009-09-17

Family

ID=39365963

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20098816001A PA8816001A1 (es) 2008-02-13 2009-02-13 Sistemas de administración de drogas que contienen estradiol

Country Status (27)

Country Link
US (1) US20110097405A1 (es)
EP (1) EP2249803A2 (es)
JP (1) JP2011511823A (es)
KR (1) KR20100125309A (es)
CN (1) CN101945646A (es)
AR (1) AR070375A1 (es)
AU (1) AU2009214193A1 (es)
BR (1) BRPI0908477A2 (es)
CA (1) CA2714340A1 (es)
CL (1) CL2009000326A1 (es)
CO (1) CO6290633A2 (es)
CR (1) CR11632A (es)
DO (1) DOP2010000252A (es)
EA (1) EA201001245A1 (es)
EC (1) ECSP10010400A (es)
IL (1) IL206640A0 (es)
MA (1) MA32073B1 (es)
MX (1) MX2010008940A (es)
NZ (1) NZ586666A (es)
PA (1) PA8816001A1 (es)
PE (1) PE20091471A1 (es)
TN (1) TN2010000302A1 (es)
TW (1) TW200940095A (es)
UA (1) UA102680C2 (es)
UY (1) UY31660A1 (es)
WO (1) WO2009101021A2 (es)
ZA (1) ZA201006517B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
GB201200062D0 (en) 2012-01-04 2012-02-15 Innotesto Bvba Estradiol oromucosal liquid compositions
CA2878680C (en) 2012-07-23 2019-09-17 Crayola, Llc Dissolvable films and methods of using the same
US10067103B2 (en) * 2015-03-02 2018-09-04 Colonaryconcepts Llc Compounds and methods for PEG metabolite and PEG breakdown product assays

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136162A (en) * 1974-07-05 1979-01-23 Schering Aktiengesellschaft Medicament carriers in the form of film having active substance incorporated therein
JPS56140915A (en) * 1980-04-07 1981-11-04 Yamanouchi Pharmaceut Co Ltd Pharmaceutical preparation for solid drug
DE3347125A1 (de) * 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption
US4764378A (en) * 1986-02-10 1988-08-16 Zetachron, Inc. Buccal drug dosage form
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5073374A (en) * 1988-11-30 1991-12-17 Schering Corporation Fast dissolving buccal tablet
WO1993023011A1 (en) * 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
DE4426709A1 (de) * 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
DE19646392A1 (de) * 1996-11-11 1998-05-14 Lohmann Therapie Syst Lts Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht
CH693255A5 (de) * 1997-06-13 2003-05-15 Eprova Ag Verwendung von Tetrahydrofolaten in der natürlichenstereoisomeren Form zur Herstellung einer pharmazeutischenZubereitung geeignet zur Beeinflussung des Homocystein-Spiegels.
AU3567699A (en) * 1998-04-17 1999-11-08 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CH693905A5 (de) * 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
US6264981B1 (en) * 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20030092658A1 (en) * 2001-02-02 2003-05-15 Meyers Rachel E. Novel human enzyme family members and uses thereof
CZ20023382A3 (cs) * 2000-04-12 2003-02-12 Schering Aktiengesellschaft Substituované estratrieny jako selektivně účinné estrogeny
EP1216712A1 (en) * 2000-12-20 2002-06-26 Schering Aktiengesellschaft Cyclodextrin-drospirenone inclusion complexes
US20030004145A1 (en) * 2001-05-16 2003-01-02 Leonard Thomas W. Treatment of conditions relating to hormone deficiencies by administration of progestins
DE20220604U1 (de) * 2001-07-27 2004-02-26 Yamanouchi Pharmaceutical Co., Ltd. Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten
DE10207394B4 (de) * 2002-02-21 2007-03-29 Lts Lohmann Therapie-Systeme Ag Geschmacksmaskierte oblatenförmige Arzneizubereitung
MEP37208A (en) * 2002-02-21 2011-02-10 Bayer Schering Pharma Ag Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12
CA2530843A1 (en) * 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
EP1695699A4 (en) * 2003-12-09 2012-08-22 Dainippon Sumitomo Pharma Co MEDICINAL GRAINS AND THE GRAINS CONTAINING SOLID PREPARATIONS
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
DE102004023984A1 (de) * 2004-05-14 2005-12-08 Hf Arzneimittelforschung Gmbh Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
DE102005015128B4 (de) * 2005-03-31 2008-12-11 Bayer Schering Pharma Aktiengesellschaft Wafer enthaltend Steroidhormone
US20060275364A1 (en) * 2005-05-26 2006-12-07 Ahmed Salah U Flexible Solid Dosage Forms and Methods of Making and Using the Same
DE102005058569B4 (de) * 2005-12-08 2010-07-15 Lts Lohmann Therapie-Systeme Ag Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer
DE102005062270A1 (de) * 2005-12-24 2007-06-28 Bayer Technology Services Gmbh Geschmacksmaskierung von Pulvern
DE102006003512A1 (de) * 2006-01-24 2007-08-02 Bayer Schering Pharma Ag Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen
EP1867321A3 (en) * 2006-06-07 2008-11-19 Familplan Consulting Ltd. A pharmaceutical product adapted for oral transmucosal administration comprising a pharmaceutical agent
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
DE102006027792A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Antidepressiva-Kombinations-Wafer
US20080058272A1 (en) * 2006-08-29 2008-03-06 Juergen Becker Nonamer Peptides for Cancer Treatment

Also Published As

Publication number Publication date
WO2009101021A3 (en) 2009-12-30
BRPI0908477A2 (pt) 2018-03-27
EP2249803A2 (en) 2010-11-17
DOP2010000252A (es) 2010-08-31
NZ586666A (en) 2012-04-27
UA102680C2 (ru) 2013-08-12
ZA201006517B (en) 2014-02-26
CN101945646A (zh) 2011-01-12
CR11632A (es) 2010-10-05
UY31660A1 (es) 2009-09-30
CL2009000326A1 (es) 2010-07-19
WO2009101021A2 (en) 2009-08-20
MX2010008940A (es) 2010-10-05
TN2010000302A1 (en) 2011-11-11
PE20091471A1 (es) 2009-10-25
IL206640A0 (en) 2010-12-30
JP2011511823A (ja) 2011-04-14
CO6290633A2 (es) 2011-06-20
KR20100125309A (ko) 2010-11-30
TW200940095A (en) 2009-10-01
US20110097405A1 (en) 2011-04-28
AU2009214193A1 (en) 2009-08-20
MA32073B1 (fr) 2011-02-01
AR070375A1 (es) 2010-03-31
ECSP10010400A (es) 2010-09-30
CA2714340A1 (en) 2009-08-20
EA201001245A1 (ru) 2011-04-29

Similar Documents

Publication Publication Date Title
CO2018012346A2 (es) Apósito para heridas o para la piel
CY1120690T1 (el) Κρυσταλλικη μορφη βενζυλοβενζολικου αναστολεα τουsglt2
NI201400109A (es) Tratamiento del cáncer con inhibidores tor cinasa
BR112016024631A2 (pt) cápsulas antimicrobianas para conectores médicos
UY30056A1 (es) Administracion transdermica de meptazinol
ECSP099634A (es) Derivados de piridazinona útiles como inhibidores de glucano sintasa
BR112016012615A8 (pt) sistemas, e kit
BR112016029781A2 (pt) composições e métodos para inibir a expressão de gene de alfa-1 antitripsina
PE20091574A1 (es) Sistema de administracion de drogas con efecto estabilizante
EP3494959A3 (en) Sustained release latanoprost implant
GT201400003A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
NI201500055A (es) Tratamiento de cáncer de próstata con inhibidores de quinasa tor
PA8816001A1 (es) Sistemas de administración de drogas que contienen estradiol
PE20150721A1 (es) Composicion farmaceutica que comprende gemigliptina y metformina, y metodo para su preparacion
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
MX2017002818A (es) Composiciones topicas de pterostilbeno para utilizarse en el tratamiento de la perdida inducida por uv de la funcion de barrera en la piel.
WO2010151004A3 (ko) 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물
CL2017002801A1 (es) Formulación de hidrogel con adhesión moderada
BR112015005392A2 (pt) formulação de comprimido de um inibidor de fosfatidilinositol 3-cinase
CL2020001926A1 (es) Uso de carbonato de calcio funcionalizado como ingrediente activo.
PH12014502323A1 (en) Oral formulation
CR20150190A (es) Composición sinérgica de nitazoxanida y mebendazol, procesos para preparla y el uso de dicha composición para el tratamiento de la parasitosis humana
CU20100164A7 (es) Sistemas de administración de drogas que contienen estradiol
NZ717880A (en) Glucopyranosyl-substituted indole-urea derivatives and their use as sglt inhibitors
ES2446215R2 (es) Aplicación terapéutica de agentes inhibidores de cd44 frente a la leucemia linfoblástica aguda (all) humana.